Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/p-catenin pathway in xenograft models of hepatocellular carcinoma

Mutations affecting the Wnt/[beta]-catenin pathway have been identified in 26-40% of hepatocellular carcinoma (HCC) cases. Aberrant activation of this pathway leads to uncontrolled cell proliferation and survival. Thus, identifying Wnt/p-catenin pathway inhibitors may benefit a subset of patients wi...

Ausführliche Beschreibung